While anti-IL-21 monotherapy potently prevents diabetes in the NOD model, it does not reverse.It was therefore opted to combine the GLP-1R agonist liraglutide with anti-IL-21, resulting in reversal after hyperglycemia onset in the NOD model. The gene discussed is GLP1R; the disease is diabetes mellitus.